Showing 101 - 120 results of 16,925 for search '(( 50 c decrease ) OR ((( 50 ((ng decrease) OR (a decrease)) ) OR ( 50 we decrease ))))', query time: 0.98s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106

    Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

    Published 2025
    “…<p>For 50 Erdős-Rényi graphs with 30 nodes and 70 edges, we split the results into two columns according to the two initial degenerate unstable eigenmodes  +  : on the left, (if ), and on the right, (if ). …”
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114

    Protective effect and mechanism of low P50 haemoglobin oxygen carrier on isolated rat heart by Wentao Zhou (5867126)

    Published 2022
    “…However, the oxygen-carrying and releasing capacity (P50) is different with different HBOCs. The aim of our study was to investigate whether STS (a kind of cardioprotective solution, St Thomas Solution) +different P50 HBOCs provide superior myocardial protection and decrease myocardial injury compared to only STS in rats Langendorff isolated heart perfusion model. …”
  15. 115
  16. 116

    Shapefiles of canopy disturbances for the 50-ha plot on Barro Colorado Island, Panama, for 2014-2019 by Raquel F. Araujo (10648181)

    Published 2021
    “…We defined a canopy disturbance as a substantial decrease in canopy height in a contiguous patch of canopy occurring over one measurement interval. …”
  17. 117

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  18. 118

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  19. 119
  20. 120